THE National Health and Medical Research Council (NHMRC) has approved the recommendations made in the 'Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine' developed by the University of Sydney in partnership with the NHMRC Cognitive Decline Partnership Centre and the Bruyre Research Institute in Canada.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 21 Feb 18
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 18
